Schizophrenia Long-acting Injectables Market

Future Market Insights

Schizophrenia Long-acting Injectables Market

Key Insight

The global schizophrenia long-acting injectables market is projected to grow from USD 6,392.7 million in 2025 to USD 11,894.6 million by 2035, at a CAGR of 6.4%. By drug type, paliperidone LAIs will lead with a 31.4% market share, while by dosing frequency, 1-month LAIs will dominate with a 48.9% share in 2025.

December 04, 2025

Anurag Sharma

250 Pages

Cite this Report

Schizophrenia Long-acting Injectables Market

https://www.futuremarketinsights.com/reports/schizophrenia-long-acting-injectables-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Aurobindo Pharma
Dr. Reddy’s
Otsuka / Lundbeck
Sun Pharma
Teva
Zydus Lifesciences Ltd

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Schizophrenia Long-acting Injectables Market

Key Players

Similar Industry Reports